Evidence map›Paper›PMID 34162683›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2021

Estimating the Breast Cancer Burden in Germany and Implications for Risk-based Screening.

Anne S Quante, Anika Hüsing, Jenny Chang-Claude, Marion Kiechle, Rudolf Kaaks, Ruth M Pfeiffer

Open access · bronzeAbstract read
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Anne S Quante *Department of Gynecology and Obstetrics, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany. anne.quante@tum.de pfeiffer@mail.nih.gov.ORCID 0000-0002-4973-3024
Anika Hüsing *Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Jenny Chang-ClaudeDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-8919-1971
Marion KiechleDepartment of Gynecology and Obstetrics, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany.ORCID 0000-0003-4237-2657
Rudolf KaaksDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0003-3751-3929
Ruth M PfeifferDivision of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland. anne.quante@tum.de pfeiffer@mail.nih.gov.ORCID 0000-0001-7791-2698
German Cancer Research Center · DECenter for Cancer Research · USTUM Klinikum · DEUniversität Hamburg · DEUniversity of Freiburg · DE

Funding

Risk prediction methodsZIACP010188 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ALBERT, PAUL · 2010 to 2025
$8.9M
Intramural NIH HHS ZIA CP010188
6 · The paper itself

Abstract

In Germany, it is currently recommended that women start mammographic breast cancer screening at age 50. However, recently updated guidelines state that for women younger than 50 and older than 70 years of age, screening decisions should be based on individual risk. International clinical guidelines recommend starting screening when a woman's 5-year risk of breast cancer exceeds 1.7%. We thus compared the performance of the current age-based screening practice with an alternative risk-adapted approach using data from a German population representative survey. We found that 10,498,000 German women ages 50-69 years are eligible for mammographic screening based on age alone. Applying the 5-year risk threshold of 1.7% to individual breast cancer risk estimated from a model that considers a woman's reproductive and personal characteristics, 39,000 German women ages 40-49 years would additionally be eligible. Among those women, the number needed to screen to detect one breast cancer case, NNS, was 282, which was close to the NNS = 292 among all 50- to 69-year-old women. In contrast, NNS = 703 for the 113,000 German women ages 50-69 years old with 5-year breast cancer risk <0.8%, the median 5-year breast cancer risk for German women ages 45-49 years, which we used as a low-risk threshold. For these low-risk women, longer screening intervals might be considered to avoid unnecessary diagnostic procedures. In conclusion, we show that risk-adapted mammographic screening could benefit German women ages 40-49 years who are at elevated breast cancer risk and reduce cost and burden among low-risk women ages 50-69 years. PREVENTION RELEVANCE: We show that a risk-based approach to mammography screening for German women can help detect breast cancer in women ages 40-49 years with increased risk and reduce screening costs and burdens for low-risk women ages 50-69 years. However, before recommending a particular implementation of a risk-based mammographic screening approach, further investigations of models and thresholds used are needed.

Indexed as

Cost of IllnessAdultAgedAge FactorsBreastBreast NeoplasmsEarly Detection of CancerFemaleGermanyHumansMammographyMiddle AgedModels, StatisticalPractice Guidelines as TopicRisk AssessmentRisk Factors

Identifiers

PMID34162683
PMCPMC8226107
OpenAlexW3133696265

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.